Baxter has agreed to sell its kidney treatment division to private equity firm Carlyle in a $3.8 billion cash deal, allowing it to pay down more debt. Skip to main content ...

On August 13, 2024, Baxter International Inc. (NYSE: BAX, $36.12, Market Capitalization: $18.4 billion), a global medtech leader, and funds managed by global investment firm Carlyle (NASDAQ: CG ...

On Tuesday, Baxter International Inc (NYSE:BAX) agreed to sell its Kidney Care segment, Vantive, for $3.8 billion to The Carlyle Group Inc (NASDAQ:CG) Baxter will receive approximately $3.5 ...

For 2023, Baxter reported kidney care accounted for $4.45 billion in sales, a 36.4% increase compared to the prior year and about 30% of Baxter’s overall sales. However, ...

US medtech giant Baxter has announced today (13 August) the signing of a definitive agreement divesting itself of the kidney care segment, handing the business over to global investment company ...

NEW YORK (Reuters) -Buyout firm Carlyle Group struck a deal to acquire Baxter’s kidney-care unit Vantive for $3.8 billion, the companies said on Tuesday. The proceeds from the deal, which is ...

Baxter's kidney business could go to Carlyle for over $4B: report By Jon Asplund Jon Asplund is a contributing reporter covering health care for Crain’s Chicago Business.

Shares of Baxter International fell Tuesday after the company said it would sell its kidney treatment division to The Carlyle Group for $3.8 billion in cash.

Baxter's Vantive unit, in the process of being sold to Carlyle, is building an R&D center in Golden Valley. The kidney care unit develops and supports dialysis and other kidney disease therapies.

Baxter International Inc. said it will sell its kidney-care unit to the Carlyle Group private equity firm for $3.8 billion, part of the health care company’s efforts to streamline and pay down debt.